أعرض تسجيلة المادة بشكل مبسط
| dc.creator |
Ekin Şavk |
|
| dc.date |
2011 |
|
| dc.date.accessioned |
2013-05-30T14:25:09Z |
|
| dc.date.available |
2013-05-30T14:25:09Z |
|
| dc.date.issued |
2013-05-30 |
|
| dc.identifier |
http://www.journalagent.com/z4/download_fulltext.asp?pdir=turkderm&plng=tur&un=TURKDERM-00378 |
|
| dc.identifier |
http://www.doaj.org/doaj?func=openurl&genre=article&issn=1019214X&date=2011&volume=45&issue=1&spage=54 |
|
| dc.identifier.uri |
http://koha.mediu.edu.my:8181/jspui/handle/123456789/6142 |
|
| dc.description |
The common therapeutic goal for all subepidermal bullous diseases is to prevent inflammation and production of pathogenic autoantibodies and/or to facilitate the elimination of these antibodies. Diseases included in this group are the pemphigoids, linear IgA dermatosis, epidermolysis bullosa acquisita, dermatitis herpetiformis and bullous systemic erythematosus. Corticosteroids are the most commonly used systemic medication. Other alternatives include dapsone, various antibiotics and nicotinamide, azathioprine, cyclophosphamide, methotrexate, cycloporine, mycophenolate mofetil, IV immunoglobulins and plasmapheresis. Rapid reepithelialization and prevention of secondary infections are provided by local hygenic measures including antiseptic baths and wound care. (Turkderm 2011; 45 Suppl 1: 54-8) |
|
| dc.publisher |
Galenos Yayincilik |
|
| dc.source |
Turkderm |
|
| dc.subject |
Subepidermal bullous disease |
|
| dc.subject |
treatment |
|
| dc.title |
Treatment of Subepidermal Autoimmune Bullous Diseases Sürekli Eğitim |
|
الملفات في هذه المادة
|
لا توجد أي ملفات مرتبطة بهذه المادة.
|
هذه المادة تبدو في المجموعات التالية:
أعرض تسجيلة المادة بشكل مبسط